Revvity, Inc. Hits New 52-Week High at USD 118.30

Revvity, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 118.30 on August 13, 2026. This achievement marks a notable increase from its 52-week low of USD 81.23, reflecting a year-over-year performance of 7.5%. The company, with a market capitalization of USD 9,380 million, operates within a competitive industry landscape. Revvity's price-to-earnings (P/E) ratio stands at 30.00, indicating its valuation relative to earnings. The firm also offers a modest dividend yield of 0.35%, appealing to income-focused investors. In terms of financial health, Revvity maintains a debt-to-equity ratio of 0.32, suggesting a conservative approach to leveraging. Additionally, the company's return on equity (ROE) is recorded at 4.36%, providing insight into its efficiency in generating profits from shareholders' equity. As Revvity continues to navigate the dynamic pharmaceutical landscape, its recent price performance underscores its current market position and operational metrics.